Acute Myeloid Leukaemia (AML) Clinical Trials

11 recruiting

Acute Myeloid Leukaemia (AML) Trials at a Glance

10 actively recruiting trials for acute myeloid leukaemia (aml) are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Barcelona, Bethesda, and Bologna. Lead sponsors running acute myeloid leukaemia (aml) studies include Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC), Jacqueline Garcia, MD, and Australian Leukaemia and Lymphoma Group (ALLG).

Browse acute myeloid leukaemia (aml) trials by phase

Treatments under study

About Acute Myeloid Leukaemia (AML) Clinical Trials

Looking for clinical trials for Acute Myeloid Leukaemia (AML)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Myeloid Leukaemia (AML) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Myeloid Leukaemia (AML) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2Phase 3

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Acute Myeloid Leukaemia (AML)Follicular Lymphoma ( FL)
Tempus AI550 enrolled5 locationsNCT07154823
Recruiting
Phase 1Phase 2

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 1

Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Acute Myeloid Leukaemia (AML)
medac GmbH36 enrolled4 locationsNCT05534620
Recruiting
Not Applicable

Maintenance Venetoclax in AML Fit Patients

Acute Myeloid Leukaemia (AML)
Sohag University80 enrolled2 locationsNCT07244367
Recruiting
Not Applicable

Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukaemia (AML)
Rigshospitalet, Denmark15 enrolled1 locationNCT07062250
Recruiting
Not Applicable

Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

Acute Lymphoblastic Leukemia ALLAcute Myeloid Leukaemia (AML)High Risk Leukaemia+1 more
University Of Perugia51 enrolled1 locationNCT06845592
Recruiting
Phase 1

An Exploratory Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers

Acute Myeloid Leukaemia (AML)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)88 enrolled1 locationACTRN12624000180516
Recruiting
Phase 2

AMLM22/D2-The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in subjects with acute myeloid leukaemia in first complete remission. Domain 2 is investigating the safety and efficacy of Venetoclax as a maintenance therapy alone or in combination with low dose cytarabine (LDAC).

Acute Myeloid Leukaemia (AML)
Australian Leukaemia and Lymphoma Group (ALLG)75 enrolled19 locationsACTRN12619000280101
Recruiting
Phase 2

Eltrombopag therapy for low platelets in patients on azacitidine treatment for myelodysplastic syndrome and acute myeloid leukaemia

Low marrow blast count acute myeloid leukaemia (AML)Myelodysplastic Syndromes (MDS)
Peter Mac Callum Cancer Centre25 enrolled1 locationACTRN12610000641099